UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF EFFECTIVENESS

Effective Date:January 17,
Boundless Bio (NASDAQ:BOLD)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse Boundless Bio
Boundless Bio (NASDAQ:BOLD)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse Boundless Bio

Actualités Audentes Therapeutics, Inc.

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Mercredi 5 Juin 2024 ( il y a 2 semaines) • Business Wire
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Lundi 13 Mai 2024 ( il y a 1 mois) • Edgar (US Regulatory)
Form 8-K - Current report
Lundi 13 Mai 2024 ( il y a 1 mois) • Edgar (US Regulatory)
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
Lundi 13 Mai 2024 ( il y a 1 mois) • Business Wire
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
Lundi 6 Mai 2024 ( il y a 1 mois) • Business Wire
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
Jeudi 11 Avril 2024 ( il y a 2 mois) • Business Wire
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
Lundi 8 Avril 2024 ( il y a 2 mois) • Business Wire

Plus d'articles sur Audentes Therapeutics, Inc.